External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study - Wikidata - awgldk - TriplyDB

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

http://www.wikidata.org/entity/Q34086969

about

Contemporary Treatment of Metastatic Renal Cell Carcinoma Current management and future directions in the treatment of advanced renal cell carcinoma-a latin american perspective: 10 years in review Cytoreductive nephrectomy and its role in the present-day period of targeted therapy.Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvement Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma Medical treatment of renal cancer: new horizons Immunotherapy for metastatic renal cell carcinoma.Renal cell carcinoma.Assessing the clinical utility of cancer genomic and proteomic data across tumor types.Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2.Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy.Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study Tetravalent antibody-scTRAIL fusion proteins with improved properties.Low CCL-21 expression associates with unfavorable postoperative prognosis of patients with metastatic renal cell carcinoma.Predictive value of the modified Glasgow Prognostic Score for the therapeutic effects of molecular-targeted drugs on advanced renal cell carcinoma.First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience.Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives.Pretherapeutic gamma-glutamyltransferase is an independent prognostic factor for patients with renal cell carcinoma.Prognostic value of components of body composition in patients treated with targeted therapy for advanced renal cell carcinoma: a retrospective case series DNA methylation biomarkers predict progression-free and overall survival of metastatic renal cell cancer (mRCC) treated with antiangiogenic therapies.IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy.SOX9 was involved in TKIs resistance in renal cell carcinoma via Raf/MEK/ERK signaling pathway.Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways.The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma.Nutritional screening is strongly associated with overall survival in patients treated with targeted agents for metastatic renal cell carcinoma A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry.Prognostic value of interleukin-6 and interleukin-6 receptor in organ-confined clear-cell renal cell carcinoma: a 5-year conditional cancer-specific survival analysis Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma.

P2860

Q26740594-5F9E3E5D-FFC4-42CC-87B6-E3BE4D1ABE3A Q26774515-8D71B0B9-2E1F-4E8D-BB1B-E2EDBD6C0943 Q26783520-0D018818-912C-4D8B-8BF0-9BF6668A3D6C Q26801279-57B25433-7EAE-45DB-811E-85168B83648A Q28067482-269AAB25-C989-422D-BA81-266508128846 Q28073174-CC593BF1-6C17-4156-8542-213861AF4487 Q30234458-C9F54848-33F3-497D-A602-F0187D06D77C Q30235364-60163640-B176-4FC2-B1DA-E9048A06FDF4 Q30487077-B5CD9BCA-119F-495D-8954-DF2A56DB45E4 Q33417828-DACBE839-43EA-4D83-8244-2F21221BA4A1 Q33423740-6C4F96F7-719C-46C6-A155-01E47C40F3DA Q33426559-19AE316D-B0ED-432C-AD27-C601E6C16C67 Q33426958-728DBBD0-511C-4810-AED4-D7CED92F6D62 Q33431578-DDC1CEBD-059D-46E5-A36D-179FBC7923E7 Q33439523-506994C7-F987-4AA1-B7C5-47B81EEF251C Q33577856-5892A1D4-9203-4940-A535-06E41790B4A7 Q33619046-39403A39-BDA4-435A-80D8-246CC28562BC Q33648983-849B0071-104C-488C-B500-CECDF2BE5A10 Q33684941-8EABD9C7-F8FB-4621-AF9F-6A01E3B7D49D Q33696649-A97D1242-75A3-457B-B3CC-00CB40606BB6 Q33814322-6977A88C-47C5-47B1-AD10-24A5170E870C Q34138032-51F0E095-B120-472C-A513-5B9106B028F5 Q34351372-ECD0CE6C-5F89-41E9-AF44-B94F14400A29 Q34354554-980389D0-96DF-49F5-AAE7-80791CDC2A6E Q35068826-CF025CD3-90D3-4D4D-ACDD-8ED6F375468E Q35122019-01EC8F28-6628-45A8-8073-829C8C8BD22F Q35274936-2B8E91A7-E71F-4ADA-AD8B-F1BBD2CFE442 Q35674216-65B0A331-4954-4AD1-A0A8-94C036F6A8DF Q35741056-3D23BBD3-6CEC-449F-8CC1-B29B8B327984 Q35802508-E5E2739A-D786-4ADE-8FAA-C18030489370 Q35832449-85AC2848-D9A0-4F57-B1CF-9C6F0F3F1F80 Q35918881-6EE02F6E-F08A-44F8-BC8E-D4C1DED6A70C Q36043473-23700F02-E5F0-4644-94E9-2D9AFF767A58 Q36074171-1E31DBEA-B077-4CB2-8619-9C7E56203056 Q36092829-ED352B60-F22E-4B2F-91F4-DBE13E04BAB2 Q36124825-ADCEEF12-99ED-4A68-B956-31E5F377273C Q36132720-394F8768-E9CD-4DDA-947C-CC74FCFC8DC8 Q36384503-263DBF27-02D3-42B1-8A7B-A4D3FAFF000C Q36443895-102CD896-551F-49C3-82F1-273E5B2D71D9 Q36855805-392B0E51-D2A1-4741-9797-C87CF234430B

P2860

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

http://www.wikidata.org/entity/Q34086969

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

External validation and compar ...... odel: a population-based study

@ast

External validation and compar ...... odel: a population-based study

@en

External validation and compar ...... odel: a population-based study

@nl

type

label

External validation and compar ...... odel: a population-based study

@ast

External validation and compar ...... odel: a population-based study

@en

External validation and compar ...... odel: a population-based study

@nl

prefLabel

External validation and compar ...... odel: a population-based study

@ast

External validation and compar ...... odel: a population-based study

@en

External validation and compar ...... odel: a population-based study

@nl

P1433

Q34086969-295199F4-F4D8-436E-8FAB-F46FEB8736E7

P1476

Q34086969-D3870707-C9A3-424C-8D25-BB82F74002CC

P2093

Q34086969-091DAB79-53AB-48AD-87A7-4D5BA210E4B0

Q34086969-1CBDE9F3-3541-466C-8E9D-36A8C399F128

Q34086969-219C1A0B-881B-498E-98EC-3DB0CC023804

Q34086969-3AF9E9C4-23B5-4B03-A519-8A4F8E1094B3

Q34086969-3F1511F2-96EE-427F-9A58-5C69BA42A32C

Q34086969-749F121B-9F4B-4BD1-A835-C8CC616173E7

Q34086969-8AF140FE-066F-47FB-9E34-15E64E049F91

Q34086969-A2CB03A1-22B7-4129-B668-8F6611D0BA6E

Q34086969-E58D36F2-83BD-4456-8C5B-44043E8C4546

Q34086969-F4A2738A-0446-4EB7-816B-15BC03423455

P2860

Q34086969-23D95D00-9DDF-4BE0-B850-B22D353C5294

Q34086969-2F6A00D3-8E82-4EB4-BF9D-F09B7D5BB258

Q34086969-50C4AA18-5F42-4A13-9ADF-FEF94B3BF6ED

Q34086969-5547F0F9-0355-47E2-B332-C27AECED675D

Q34086969-60B588A3-55B2-4102-B30D-21DA95D5B4CF

Q34086969-79700949-0CCD-47F1-8F6E-6CC89BF13727

Q34086969-7E738BA3-2B5E-4831-8879-06D7AA2CD0F2

Q34086969-851C5FFD-E12C-46F8-A047-52F82A0CEF4F

Q34086969-A6E689F6-F254-47A9-BB4D-749AC996FB81

Q34086969-B74BD833-84AC-4348-84C3-186042879C21

P304

Q34086969-6CD30DF4-F4B1-4D6E-A5DC-740DEB5210E7

P31

Q34086969-5777012E-6D7C-41A4-832A-12FA151B441B

P356

Q34086969-7DD017B6-8848-4A04-A4E0-4DDD5350B92E

P433

Q34086969-4A23C374-67B9-4235-B5F1-29F89C936001

P478

Q34086969-AF840759-14DB-4BA2-AB8F-04E972068FAE

P50

Q34086969-147DE787-0988-4D44-AD7B-4FD8601D57D6

Q34086969-81289AF9-3477-4C56-B303-DA1B0ED76D5E

Q34086969-AAF921D1-CE82-4A4D-A456-CD523961A646

P577

Q34086969-C38C1633-F4E7-46C3-A124-C0368B3A9DA2

P5875

Q34086969-335D4B8D-FB19-4123-9217-5262FD3436E3

P698

Q34086969-6850674F-EB70-4317-87EA-5443D7083554

P921

Q34086969-18FC108E-039C-4825-A835-F0BEF8520C49

P932

Q34086969-7E0E48CB-09EF-4B30-ACA0-1D5F1A892AD3

P356

S1470-2045(12)70559-4

P1433

The Lancet Oncology

P1476

External validation and compar ...... odel: a population-based study

@en

P2093

Brian I Rini

http://www.w3.org/2001/XMLSchema#string

Christian Kollmannsberger

http://www.w3.org/2001/XMLSchema#string

Daniel Y C Heng

http://www.w3.org/2001/XMLSchema#string

Lauren C Harshman

http://www.w3.org/2001/XMLSchema#string

Lori Wood

http://www.w3.org/2001/XMLSchema#string

Mary Mackenzie

http://www.w3.org/2001/XMLSchema#string

Meredith M Regan

http://www.w3.org/2001/XMLSchema#string

Min-Han Tan

http://www.w3.org/2001/XMLSchema#string

Neeraj Agarwal

http://www.w3.org/2001/XMLSchema#string

Toni K Choueiri

http://www.w3.org/2001/XMLSchema#string

P2860

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond

Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort.

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group.

P304

141-148

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(12)70559-4

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Georg A. Bjarnason

P577

2013-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234121625

http://www.w3.org/2001/XMLSchema#string

P698

23312463

http://www.w3.org/2001/XMLSchema#string

P921

P932

4144042

http://www.w3.org/2001/XMLSchema#string